Follow us on Twitter
twitter icon@FreshPatents


Obesity patents

      

This page is updated frequently with new Obesity-related patent applications.

Cell-permeable (cp)-delta socs3 recombinant protein and uses thereof
The present invention is related to development of the improved cell-permeable (cp)-Δsocs3 recombinant protein which disrupt the interaction of leptin receptor (obr) and suppressor of cytokine signaling 3 (socs3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.. .

Aryl acylsulfonamides as blt1 antagonists
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer..

Compositions and methods for the treatment of metabolic and related disorders
The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin a and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an a-b-c tripartite structure, wherein a, b, and c are identical or non-identical structures and are described in detail herein.

Monocarboxylate transport modulators and uses thereof
The invention generally relates to the field of monocarboxylate transport modulators, e.g., monocarboxylate transport inhibitors, and more particularly to new substituted-quinolone compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in treating, modulating, forestalling and/or reducing physiological conditions associated with monocarboxylate transport activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, obesity, diabetes, cardiovascular diseases, tissue and organ transplant rejection, and malaria.. .

Identification of cyclic peptide agonists of galanin receptor 2 and 3 guided by spexin solution structure
Cyclic peptide agonists toward human galanin receptor 2 (galr2) and galanin receptor 3 (galr3) based on hidden conformation of spexin solution structure for galr2 and galr3-related and spexin-deficient disorders are designed and synthesized. Lh101, lh102, and lh101 (ac) are potent spexin analogs with prolonged action, which can be used in the treatment of galr2 and galr3-related diseases and spexin-deficient disorders, such as obesity..

Treatment of adipocytes
The present disclosure provides compositions comprising a lyn kinase activator and trpm8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, syndrome x, obesity, prediabetes, type ii diabetes, type i diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.. .

Flavonolignans for treatment of autoimmune inflammatory diseases
A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome.

Use of l. reuteri for recovery of microbiota dysbiosis in early life
The invention concerns lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of actinobacteria and increased levels of proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions.

Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring
The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation.

Antibacterial and protective bacteriophage formulations and methods for making and using them
Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel.
San Diego State University (sdsu) Foundation Dba San Diego State University Research Foundation


Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Composition for preventing or treating menopausal disorders, containing tetragonia tetragonoides (pall.) kuntze extract

The present invention relates to: a pharmaceutical composition for preventing or treating menopausal disorders, containing a tetragonia tetragonoides (pall.) kuntze extract or a fraction thereof; a method for preventing or treating menopausal disorders, comprising a step of administering the pharmaceutical composition; and a food composition containing the extract or a fraction thereof. The tetragonia tetragonoides (pall.) kuntze extract of the present invention shows effects of alleviating obesity, which is representative of glucose metabolism disorders and lipid metabolism disorders, osteoporosis, which is representative of bone homeostasis disorders, and flushing, which is representative of energy metabolism disorders, and thus the extract can be used in food, a medicine and the like so as to prevent, alleviate or treat menopausal disorders..
Korea Institute Of Oriental Medicine

Compositions and methods for white to beige adipogenesis

Disclosed herein are compositions and methods for transitioning or converting a white adipocyte to a beige adipocyte. The compositions and methods may be used in the treatment of obesity.

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Vitamin d3 derivatives and pharmaceutical use thereof

The present invention relates to vitamin d3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesity, diabetes, cardiovascular disease, or cancer in a patient in need thereof.. .
National University Corporation Tokyo University Of Agriculture And Technology

Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists

Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-ht(2c) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-ht(2c) receptors provides a benefit, such as obesity and psychiatric disorders.. .
The Board Of Trustees Of The University Of Illinois

Composition for prevention, amelioration or treatment of metabolic syndrome

The mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.. .

Method of preventing obesity and cardiovascular problems in poultry

Provided is a feed for ameliorating weight gain in poultry comprising 25-hydroxy vitamin d, canthaxanthin, vitamin e and vitamin c. Animals fed this composition gained weight, but did not become obese, nor did they experience adverse effects associated with hyperphagia related obesity.
Dsm Ip Assets B.v.

Intragastric device for treating obesity

An intragastric device including (1) a first wire mesh structure having a pre-deployment shape, a post-deployment shape greater than the pre-deployment state, and one or more openings on an upper portion of the first wire mesh structure that are configured to permit food to enter the device, (2) a second wire mesh structure having a pre-deployment shape a post-deployment shape greater than the pre-deployment state, and one or more openings on a lower portion of the second wire mesh structure that are configured to permit food to exit the device. A sleeve may be coupled to the lower portion of the wire mesh structure.
Synerz Medical, Inc.

A pharmaceutical composition for treating or preventing obesity

Melanophilin (mlph) of the present invention is involved in differentiation into an adipocyte or fat accumulation, and accordingly, obesity can be treated or prevented by inhibiting the mlph. Further, by measuring an expression level of the mlph, obesity can be diagnosed and treated, and therapeutic agents for obesity and agents regulating differentiation into adipocytes can be screened..

Gip peptide analogues

Provided herein are glucose-dependent insulinotropic polypeptide (gip)-derived peptide analogues, for example gip(3-30), and their use as antagonists of the gip receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.. .

Heteroaryl compounds and methods of use thereof

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..

Method of using a mangifera indica composition in the treatment of obesity

The invention relates to a herbal composition derived from mangifera indica. Methods of making and using the composition for the management of obesity are also contemplated..

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .

Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases

The object of the invention are compositions and medical treatment methods with an inheritable, gram-negative, strictly anaerobic and commensal bacterium of the family christensenellaceae belonging to an otu (operational taxonomic unit) characterized by a 16s rrna sequence seq id no: 1 or to an otu characterized by a165 rrna sequence seq id no: 2.. .

Specific bacteria for their use as a medicament, in particular for controlling excess weight, obesity, cardiometabolic diseases and inflammatory bowel diseases

The object of the invention are compositions and medical treatment methods with an inheritable, gram-negative, strictly anaerobic and commensal bacterium of the family christensenellaceae belonging to an otu (operational taxonomic unit) characterized by a 16s rrna sequence seq id no: 1 or to an otu characterized by a 16s rrna sequence seq id no: 2.. .

Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Wherein the groups r1, r2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin o-acyl transferase (goat) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity..

Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided.
Zafgen, Inc.

Azetidine compounds as grp119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present disclosure relates to azetidine compounds. The azetidine compounds are gpr119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders.
Sanofi

Devices for and methods of treatment of metabolic syndromes

Devices for and methods of treatment of metabolic syndromes are disclosed. Namely, the presently disclosed devices and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic syndromes.
The Johns Hopkins University

Fgf21 compound / glp-1r agonist combinations with optimized activity ratio

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an fgf21 (fibroblast growth factor 21) compound and a glp-1r (glucagon-like peptide-1 receptor) agonist with optimized glp-1r agonist/fgf21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (nash) and/or atherosclerosis..
Sanofi

Pharmaceutical composition for treating a metabolic syndrome

The invention is directed to a pharmaceutical composition containing at least one fgf-21 (fibroblast growth factor 21) compound, at least one glp-1r (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one dpp-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.. .
Sanofi

Mannose derivatives useful for treating pathologies associated with adherent e. coli

The mannose derivatives of formulae (i) are useful for treating pathologies associated with the presence of adherent escherichia coli (aec), in particular inflammatory bowel diseases (ibd), such as crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.. .

Pharmaceutical composition containing bay 11-7082, parthenolide or dimethylfumarate or a combination thereof for the treatment of obesity or cardiovascular diseases

The present invention relates to the treatment and/or prophylaxis of obesity and/or an nadph superoxide anion (o2.−) associated cardiovascular disease.. .

Apparatus and methods for treatment of morbid obesity

Apparatus and methods are described for treatment of morbid obesity using minimally invasive techniques. The apparatus includes a system of components that may be used separately or in combination for effectively reducing stomach volume, bypassing a portion of the stomach and/or small intestines, reducing nutrient absorption in the stomach and/or small intestines and/or depositing minimally or undigested food farther than normal into the intestines, thereby stimulating intestinal responses.
Valentx, Inc.

Fumagillol heterocyclic compounds and methods of making and using same

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided.
Zafgen, Inc.

Composition and treatment of metabolic disorders

The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders.
The Johns Hopkins University

Adiponectin secretion enhancer

The present disclosure provides for the administration of β-nmn, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can he ingested in order to increase the secretion of adiponectin.
Oriental Yeast Co., Ltd.

Macrocyclic ghrelin receptor modulators and methods of using the same

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, ghs-r1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein.
Ocera Therapeutics, Inc.

Compositions for use in the treatment of diabetes

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof.
University Of Ulster

Therabiome, Llc

. .

Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of formula i as tdo2 inhibitors.

Electrode placement and stimulation based on brown adipose tissue temperature

Systems and methods for spinal cord electrode placement and spinal cord stimulation their use for treatment of conditions such as obesity are disclosed. In one example approach, during placement of a spinal cord stimulating electrode in a target region of the brain of a patient, a temperature of brown adipose tissue may be monitored, e.g., via a supraclavicular temperature sensor implanted in the patient, and used to identify an optimal location of electrode stimulation which causes an increase in bat temperature.
Oregon Health & Science University

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Glycerol-3-phosphate phosphatase activators

The present disclosure relates to the identification and the use of activators of a mammalian glycerol-3-phosphate phosphatase (hg3pp) for increasing gro3p conversion to glycerol and glycerol release from a mammalian cell. The activators of hg3pp can be used in the prevention, treatment and/or alleviation of symptoms associated with obesity, type 2 diabetes and/or metabolic syndrome x.
Val-chum, Limited Partnership

Treatment of obesity using non-daily administration of 6-o-(4-dimethylaminoethoxy) cinnamoyl fumagillol

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of, e.g., a metap-2 inhibitor.. .
Zafgen, Inc.

Forma Therapeutics, Inc.

. .

Method of treating melanocortin-4 receptor pathway-associated disorders

The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (mc4r) agonist.. .
Rhythm Pharmaceuticals, Inc.

Tetrahydro-azepinoquinolines as agonists of the 5-ht2c receptor

Certain tetrahydro-azepinoquinolines of structural formula i are agonists of the mammalian 5-ht2c receptor, and, in particular, are selective agonists of the mammalian 5-ht2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-ht2c receptor, such as obesity, obesity-related conditions, and certain cns-related disorders, including schizophrenia and depression.
Sunnylife Pharma, Inc.

Monoamine reuptake inhibitors

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin.
Research Triangle Institute

Formulations for weight loss and methods of use

A weight loss composition including banaba leaf extract, apple fruit extract, rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, salacia extract, berberine, inositol, or mixtures thereof.
Golo Llc

5-ht2c receptor agonists and compositions and methods of use

Provided in some embodiments are compounds of formula a, as defined herein, that modulate the activity of 5-ht2c receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea..
Arena Pharmaceuticals, Inc.

Anti-laminin4 antibodies specific for lg4-5

The invention provides antibodies that specifically bind to the lg4-5 modules of the g domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue.
Prothena Biosciences Limited

Carbamate compounds and methods of making and using same

This disclosure provides compounds and compositions which may be modulators of magl and/or abhd6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition..
The Scripps Research Institute

Composition containing nad for preventing and treating obesity or impaired glucose tolerance

A pharmaceutical composition containing nicotinamide adenine dinucleotide (nad) as an active ingredient for preventing and treating obesity or impaired glucose tolerance, a food composition, and a method for preventing and treating obesity or impaired glucose tolerance using the same is disclosed. The nad remedies an abnormal food intake pattern of an obese animal model induced by the intake of a high-fat diet and increases mobility, thereby exhibiting an effect of suppressing the weight increase due to the high-calorie intake and also showing an effect of improving glucose tolerance.
University Of Ulsan Foundation For Industry Cooperation

Compositions and methods for treating, preventing, or alleviating obesity or related diseases

A composition comprising azelaic acid as an active ingredient suppresses accumulation of lipids in adipose tissue and improves lipid metabolism in adipose tissue.. .
Korea University Research And Business Foundation

Modified food extraction and obesity treatment

A device that is inserted through the abdominal wall and into the digestive tract of a human is disclosed. The device may be placed through a method such as percutaneous endoscopic gastrostomy (peg).
Ethicon, Inc.

Inhibiting ctrp5 action to improve insulin resistance associated with obesity and type 2 diabetes

The presently disclosed subject matter relates to methods of improving insulin sensitivity in cells, tissues, and subjects, as well as methods of reducing insulin resistance, improving glucose homeostasis, reducing hepatic tryglyceride levels, reducing food intake, and treating metabolic disorders, such as those occurring in individuals who are obese, diabetic, and/or have hepatic steatosis.. .
The Johns Hopkins University

Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer

Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer..
The Uab Research Foundation

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Inhibitory compositions

The present invention related to a composition comprising a pentose and one or more polyphenolic compounds, and to the use of said compositions for managing or reducing glucose and/or lipid absorption in a subject, and/or calorie absorption from dietary protein, carbohydrate and/or fat in a subject. The composition may be used to inhibit one or more enzymes selected from α-glucosidase, inhibitory compositions α-amylase, lipase and protease.
Inqpharm Group Sdn Bhd

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds and the uses of such compounds for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension.. .

Passive caloric bypass device

A novel medical device for treating obesity is disclosed. The device is inserted through the oral cavity and into the digestive tract of a human.
Ethicon, Inc.

Substrate selective inhibitors of insulin degrading enzyme (ide) and uses thereof

Provided herein are compounds of formulae (rl), (i), (ii), (iii), (iv), and (v), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity).
President And Fellows Of Harvard College

Compounds for the treatment of obesity and methods of use thereof

Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients.
The Children's Medical Center Corporation

Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection..
The University Of British Columbia

Anti-obesity composition comprising natural complex

A pharmaceutical composition and a health food composition for preventing, treating and improving obesity, which include an extract complex of bamboo leaves and quince as an active ingredient, are disclosed. Because the extract complex has an excellent anti-obesity effect without causing any side effects, the extract complex can be effectively used in a pharmaceutical composition and health food for preventing, improving and treating obesity.
Megabiowood Co., Ltd.

Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, alzheimer's disease, parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided.
Concordia University

Chimeric fibroblast growth factor 19 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Chimeric fibroblast growth factor 21 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf21 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

5-ht2c receptor agonists and compositions and methods of use

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
Arena Pharmaceuticals, Inc.

6-aminoisoquinoline compounds

6-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided.
Aerie Pharmaceuticals, Inc.

Exendin-4 derivatives as dual glp1/glucagon agonists

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in treating atherosclerosis and cardiovascular disease

A composition comprising extracts containing oil palm phenolics in an amount effective for use in a method of reducing cholesterol biosynthesis and thus preventing obesity. The composition up regulates fatty acid beta oxidation and down regulates cholesterol biosynthesis in livers.
Malaysian Palm Oil Board

Synthetic composition for microbiota modulation

A human milk oligosaccharide (hmo) or a synthetic composition comprising said hmo, for use in increasing the abundance, particularly the relative abundance, of a bifidobacterium of the b. Adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human.
Glycom A/s

Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders

The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the hpa axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., percodan®, percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, adhd, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., prader willi syndrome), obesity, depression, menopause, premenstrual syndrome (pms), obsessive compulsive disorder (ocd), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.. .
Embera Neurotherapeutics, Inc.

Compounds for the treatment of obesity and methods of use thereof

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients.
The General Hospital Corporation

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Method for controlling differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating sirt1 expression

The present disclosure relates to a method for controlling the differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating sirt1 (silent mating type information regulation 2 homolog; sirtuin 1) expression, the method, which controls the differentiation of embryonic stem cells into adipocytes by regulating sirt1 expression, being capable of controlling the inhibition or promotion of adipocyte differentiation in accordance with the timing of a sirt1 expression inhibitor treatment. Furthermore, kidney precursor cell differentiation can be regulated by a sirt1 expression inhibitor or promoter treatment.
Chonbuk National University Hospital

Radiosurgical neuromodulation devices, systems, and methods for treatment of behavioral disorders by external application of ionizing radiation

Radiosurgical techniques and systems treat behavioral disorders (such as depression, obsessive-compulsive disorder (“ocd”), addiction, hyperphagia, and the like) by directing radiation from outside the patient toward a target tissue within the patient's brain, typically without imposing surgical trauma. The target will often be included in a neural circuit associated with the behavioral disorder.

Methods of treating metabolic syndrome using dopamine receptor agonists

The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from metabolic syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier..
Veroscience, Llc

Traditional chinese medicine composition for promotion of browning of white adipocytes, preparation method and use thereof

A traditional chinese medicine composition for promotion of browning of white adipocytes, as well as a preparation method and use thereof are provided. The traditional chinese medicine composition of the present invention is made of fructus hippophae, piper nigrum and radix glycyrrhizae.
Infinitus (china) Company Ltd.

Traditional chinese medicine composition for promotion of browning of white adipocytes, preparation method and use thereof

A traditional chinese medicine composition for promotion of browning of white adipocytes, as well as a preparation method and use thereof are provided. The traditional chinese medicine composition is made of radix astragali seu hedysari, piper nigrum and radix glycyrrhizae.
Infinitus (china) Company Ltd.

Bifidobacteria as probiotic foundation species of gut microbiota

This invention relates to novel probiotic bifidobacteria strains, particularly, a b. Pseudocatenulatum strain, and its use as probiotic, and food products, feed products, dietary supplements and pharmaceutical formulations containing them.
Perfect (china) Co., Ltd.

Obesity treatment devices, systems, and methods

Various devices, systems, and methods that can be used in the treatment of obesity and related illnesses are disclosed. In some instances, a portion of the bowel of an obese patient is distended for a therapeutically effective period.

Fgf receptor ligands for treating diabetes and obesity

Methods for treating diabetes or obesity are provided comprising administering to the subject an amount of an agent that binds a central nervous system fgf receptor homodimer.. .
Albert Einstein College Of Medicine, Inc.

Use of a statin compound as local drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Method of medical treatment of a patient under total submergence in water completely surrounding and affecting the patient's organism

The invention relates to a medical use of water exerting a hydrostatic pressure higher than 1.1 bar, completely surrounding and affecting a patient's organism under total submergence, for use in prophylaxis, physiotherapy, rehabilitation and therapy of disorders, defects and injuries of skeletal system, arthroskeletal system, musculoskeletal system and other body systems such as circulatory system, nervous system, immune system, as well as pain conditions, such as migraine, myalgia and neuralgia, skin diseases, fertility disorders, potency dysfunctions, as well as overweight, obesity and defects of posture. According to the invention the hydrostatic pressure of water is preferably higher than 1.2 bar, and the patient is human being.

Pharmaceutical composition for preventing and treating obesity or liver diseases, containg tlr7 agonist

The present invention is based on the fact that imiquimod, which is a substance that enhances toll-like receptor 7 (tlr7) related to the innate immunity of a living body, is effective in the prevention and treatment of obesity or liver disease, and the present invention relates to a pharmaceutical composition for the prevention and treatment of obesity or liver disease, wherein the tlr7 agonist used for the immune system disease inhibits fatty acid synthetase (fas), activates autophagosome or inhibits igf-1.. .
Knotus Life Science Inc.

Nutritional compositions containing butyrate and uses thereof

Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for reducing the incidence of obesity and metabolic syndrome in a target subject via administering the nutritional composition containing dietary butyrate to the target subject.
Mead Johnson Nutrition Company

Compounds as peptidic glp1/glucagon/gip receptor agonists

The present invention relates to trigonal glp-1/glucagon/gip receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Sanofi

Compounds as peptidic trigonal glp1/glucagon/gip receptor agonists

The present invention relates to trigonal glp-1/glucagon/gip receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.. .
Sanofi

Therapies for obesity, diabetes and related indications

The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.. .
Palatin Technologies, Inc.

Methods for treating overweight or obesity

The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 ml of water per gram of crosslinked carboxymethylcellulose.
Gelesis, Llc

Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Pharmaceuticals compositions comprising the 2s, 4r, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2r, 4s ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, metabolic syndrome, and other diseases and conditions, including but not limited to cushing's syndrome, depression, and glaucoma.. .
Cortendo Ab (publ)

Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria

Provided is a composition containing lactobacillus reuteri elf corresponding to a novel lactic acid bacteria strain and 5-aminolevulinic acid. The composition may be significantly effective to prevent and treat degenerative brain disease and have excellent anti-obesity and anti-diabetes effects, such that the present invention may provide various pharmaceutical composition, health foods, and the like, using the same..
Wedea Inc.

Method of epigenetic analysis for determining clinical genetic risk

The present invention provides a method for identifying a subject having or at risk of having a metabolic disease, such as diabetes or obesity. The invention is based on an approach to identify candidate genes involved in metabolic diseases, such as obesity and type 2 diabetes (t2d) through epigenetic mechanisms.
The Johns Hopkins University

Combination compositions and their use in methods for treating obesity and obesity-related disorders

The present invention relates to compositions comprising at least two different active compounds and the use of such combination compositions in medicine, in particular in methods for treating obesity and obesity-related disorders and/or in methods for inhibiting weight gain.. .
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (gmbh)

Acylated glucagon analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Zealand Pharma A/s

Autotaxin inhibitors and uses thereof

Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases)..
National And Kapodistrian University Of Athens

Method of treating focal segmental glomerulosclerosis

A method of treating focal segmental glomerulosclerosis with a compound of formula i is provided. Fsgs may be primary (no known cause) or secondary.
Chemocentryx, Inc.

Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening

The invention relates to isolation of adipocyte-derived exosomes from a biological sample, as well as methods, compositions and kits for detecting an obesity-related disorder, for detecting risk of having an obesity-related disorder, for screening or identifying a therapy for an obesity-related disorder, for screening or identifying a therapeutic agent for an obesity-related disorder, and for treating or preventing an obesity-related disorder.. .
Children's National Medical Center

Methods of treating obesity with anti-angptl8 antibodies

The present invention provides antibodies that bind to angptl8 and methods of using the same. According to certain embodiments, the invention includes methods of using anti-angptl8 antibodies that bind human angptl8 with high affinity to treat obesity, reduce body fat, reduce body weight, increase energy expenditure, and increase hdl-c, in a subject..
Regeneron Pharmaceuticals, Inc.

Enrichment methods for preparing tannic acid compositions

Methods for preparing tannic acid-containing compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions), particularly those having enriched tannic acid populations with superior potency, purity and safety profile. Also provide herein are the tannic acid-containing compositions for use in inhibiting d-amino acid oxidase and/or for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia..
Syneurx International (taiwan) Corp.

A predicting the risk of incidence of chronic kidney diseases

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Sphingotec Gmbh

Methods for controlling obesity using minimally invasive means

Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.. .

Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

Z4, z7, z9, z11, z22, z23, z26, z30, z34, z35, p, m, n, q, and bridge are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof.

Eckol derivatives, methods of synthesis and uses thereof

Provided herein are eckol derivatives, methods of synthesis thereof and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, alzheimer's disease, microbial infections, obesity, diabetes, cancer or inflammation using the compounds and pharmaceutical compositions disclosed herein..
Phloronol, Inc.

Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives.
Reviva Pharmaceuticals, Inc.

Human catestatin induces gut microbiota dysbiosis

Treatment with catestatin changes the proportion of two major phyla bacteroidetes and firmicutes in the gut microbiota in an opposite manner observed in intestinal disorders like ibd, ibs or non-intestinal disorders like obesity. Specifically, administration of an effective amount of catestatin increased the relative percentage of bacteroidetes and decreased the relative percentage of firmicutes in the gut microbiota..
University Of Manitoba

Formulations for the treatment and prevention of obesity

Mixed with suitable excipients.. .

Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease

The present invention relates to a functional composition for preventing, alleviating or treating bone disease and lipid-related metabolic disease, and more particularly to a composition which comprises a combination of probiotics and a vitamin complex, which is capable of effectively preventing, alleviating or treating bone disease, obesity and lipid-related metabolic disease by synergistic effects on antioxidant activity, a reduction in blood lipid levels and the promotion of in vivo absorption of calcium and iron.. .
Cell Biotech Co., Ltd.

Probiotic compositions for improving metabolism and immunity

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera ileibacterium and dubosiella, including their species i.
New York University

Compositions comprising cinnamaldehyde and zinc and methods of using such compositions

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The cinnamaldehyde is supplemented by zinc, and the combination can be effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation.
Nestec S.a.

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Methods and formulations for modulating lyn kinase activity and treating related disorders

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., syndrome x), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type ii diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence..
Melior Pharmaceuticals I, Inc.

Pressure control system for intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and devices for inflating and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Melanocortin receptor ligands modified with hydantoin

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.. .
Ipsen Pharma S.a.s.

Peptide with anti-obesity and anti-diabetes activity and use thereof

A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of pparγ, acc, and ap2, which are adipogenic markers, increase the expression of phsl, ampk-α1, cgi-58, and atgl, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values.
Caregen Co., Ltd.

Fto inhibitors

The invention provides compounds that inhibit fto (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition..
National Institute Of Biological Sciences, Beijing

Composition for preventing or treating obesity or lipid-related metabolic disease

The present invention provides a pharmaceutical composition and a food composition for preventing or treating lipid-related metabolic disease, which contain, as active ingredients, probiotics and a vitamin b complex. When the composition comprising the probiotics and the vitamin b complex is used, it may further promote in vivo absorption of the vitamin b complex, and may induce a synergistic effect on a reduction in blood lipid levels, thereby exhibiting an effect on the alleviation, prevention or treatment of obesity and lipid-related metabolic disease..
Cell Biotech Co., Ltd.

Pharmaceutical compositions for combination therapy

The present application relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a fxr mediated disease or condition, such as nafld and nash, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity..
Intercept Pharmaceuticals, Inc.

Modulators of farnesoid x receptor and methods for the use thereof

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.. .
Xiamen University

Systems and methods for determining failure of intragastric devices

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Neural stem cell therapy for obesity and diabetes

Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) iκb kinase (ikkβ) activation of nuclear factor kappa-light-chain-enhancer of activated b cells (nf-κb) or (ii) notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity’..
Albert Einstein College Of Medicine, Inc.

Analogs of glucagon exhibiting gip receptor activity

Provided herein are glucagon analogs which exhibit potent activity at the gip receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an ec50 at the gip receptor which is within the nanomolar or picomolar range..
Hoffmann-la Roche Inc.

Peptide analogs for treating diseases and disorders

Provided herein are methods for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences seq id no: 12, seq id no: 15 and seq id no: 17 are administered..
Keybioscience Ag

Novel cyclosporin derivatives and uses thereof

Or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.. .

Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity

Use of saffron and its active ingredients, such as safranal and/or picrocrocin and/or crocin and/or derivatives thereof, for the production of an active satiation agent for the treatment of problems of overweight.. .

Female menopause alleviation use of composition containing composite extract of red clover and pomegranate as active ingredient

The present invention relates to: a natural composition containing a composite extract of pomegranates and red clover, exhibiting synergistic effects with respect to a menopausal symptom alleviation effect, an estrogen-like effect, an anti-obesity effect, a hyperlipidemia inhibitory effect, a fatty liver protective effect, an osteoporosis inhibitory effect and the like without any side effects; and various uses thereof, in particular, pharmaceutical, bromatological and cosmetic uses.. .
Hlscience Co .. Ltd

Water extract for promotion on hyperlipidemia, atherogenesis and obesity

The invention provides a water extract of yan-sheng-yin (ysy), a chinese natural dietary supplement for health promotion, comprised entirely of natural foods and a preparation comprising the same. The invention also provides a method for treatment and/or prevention of hyperlipidemia, atherogenesis and obesity..
Taipei Medical University

Compositions and methods for managing weight

The present disclosure provides diels-alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such diels-alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like..
Unigen, Inc.

Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others.
Volant Holdings Gmbh

Acylated glucagon analogue

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Boehringer Ingelheim International Gmbh

Cyclohexenyl compounds, compositions comprising them and uses thereof

Compositions that include certain phenyl substituted cyclohexenyl compounds are administered to a subject in a method for treating obesity or an associated disease or disorder or in a method of reducing food consumption or body weight.. .
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Use of human small leucine zipper protein in adipocyte differentiation procedure

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, slzip binds with pparγ2 to induce the formation of a complex of hdac3 and pparγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of pparγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor..
Korea University Research And Business Foundation

Compositions containing tannic acids and uses thereof

Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are d-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.. .
Syneurx International (taiwan) Corp.

Use of long-acting glp-1 peptides

The invention relates to use of long-acting glp-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.. .
Novo Nordisk A/s

Anti-obesity composition comprising pine needle juice powder as effective component

An anti-obesity composition comprises pine needle juice powder as an effective component. Because it is found that, not only a significantly higher extraction yield is obtained and a higher inhibitory activity on differentiation of an adipocyte is obtained when an extract is produced by using pine needle juice powder obtained by juicing process instead of using dry pine needle which has not been treated with any juicing process, but also both the body weight and weight of white adipose tissues are lowered and content of total lipid, total cholesterol, and triglyceride in blood is significantly lowered according to oral administration of the pine needle juice powder of the present invention to a model mouse under high fat diet, the pine needle juice powder of the present invention can be more advantageously used for a pharmaceutical composition or a functional health food for prophylaxis or treatment of obesity..
Industry-academic Cooperation Foundation, Chosun University

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Efficiently building nutrition intake history from images of receipts

This invention provides an efficient and feasible method, system and computer program for retrieving total nutrition facts from purchase transaction information including receipt images and other complementary data. The said facts are used to build up the nutrition intake history, provide nutrition intake reports and customized nutrition suggestions based on the users' personal health related information and nutrition intake data.
Whatubuy Llc

Sab as a biomarker for degenerative diseases and therapeutic sensitivity in cancers

The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of src homology 3 domain binding protein 5 (sh3bp5 or sab) or the rna encoding sab protein in a biological sample obtained from the subject and identifying the subject as having the disease or having an increased likelihood of developing the disease if the biological sample obtained from the subject has an altered level of sab protein or the rna encoding sab protein relative to a control sample.
The Florida International University Board Of Trustees

Method for decreasing the body fat content in a subject by administering an actriib protein

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.. .
Acceleron Pharma Inc.

Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor..
Remd Biotherapeutics, Inc.

Growth differentiation factor 15 (gdf-15) constructs

Constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder.
Amgen Inc.

Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided.
Zafgen, Inc.

Heteroaryl compounds and methods of use thereof

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (i) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification]..
Takeda Pharmaceutical Company Limited

Inhibitors of histone deacetylase

Or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein x1, x2, x3, x4, x5, w1, w2, w3, and w4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them.

Diphenethylamine derivatives which are inter alia useful as analgesics and their production

Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurode-generative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e.g. Esters, ethers, amides), processes for their preparation and their application in the manufacture of pharmaceutical products..
University Of Innsbruck

Injection composition comprising hyaluronidase for removal of topical fat

The present invention relates to an injection composition comprising hyaluronidase for topical fat reduction. More particularly, the present invention relates to an injection composition comprising 300 iu to 600 iu of hyaluronidase and a local anesthetic, an antihistamine, a lipolysis stimulator and a collagen production stimulator.

Amylin analogues

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation..
Boehringer Ingelheim International Gmbh

Carbazole-containing sulfonamides as cryptochrome modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula i wherein the variable r1, r2, r3, r4, r5, r6, r7, a, b, c′, d, e, f, g, h′, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula i to treat a cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, cushing's syndrome, and glaucoma..
Reset Therapeutics, Inc.

Tesofensine, beta blocker combination formulation

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder..
Saniona A/s

Identification of bitter ligands that specifically activate human t2r receptors and related assays for identifying human bitter taste modulators

The present invention relates to the discovery that specific human taste receptors in the t2r taste receptor family respond to particular bitter compounds. Also, the invention relates to the discovery of specific ht2r9 alleles and their disparate activity in functional assays with the same biter ligands.
Senomyx, Inc.

Clinical predictors of weight loss

Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent.
The General Hospital Corporation D/b/a Massachuset

Pharmaceutical composition for preventing and treating endocrine disrupting chemicals-induced diseases and treating method using the same

A pharmaceutical composition for preventing and treating endocrine disrupting chemicals-induced diseases and a treating method using the same. Since the composition has an effect of decreasing lipid accumulation caused by endocrine disrupting chemicals, for example, persistent organic pollutants (pops) including polychlorinated biphenyl and the like and can improve insulin resistance caused by the pops through reduction of insulin receptor substrate 1 (ir1), the composition can be helpfully used for treating diseases including obesity, insulin resistance, and the like caused by the endocrine disrupting chemicals.
Dong-a University Research Foundation For Industry-academy Cooperation

Indazole derivatives useful as glucagon receptor antagonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Indazole derivatives useful as glucagon receptor antagonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Tesofensine compositions

The present invention relates to tesofensine compositions, methods to prepare the same and uses thereof in preparing medicines for the prevention and treatment of overweight, obesity and type 2 diabetes mellitus.. .
Saniona A/s

Indole derivatives useful as glucagon receptor antagonists

The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as type ii diabetes mellitus and obesity.. .
Janssen Pharmaceutica Nv

Methods of treating an overweight or obese subject

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a metap2 inhibitor in which the amount administered does not substantially modulate angiogenesis..
Zafgen, Inc.

Agents useful for treating obesity, diabetes and related disorders

This invention provides methods of treatment diabetes and related conditions using idebenone and analogs thereof compounds 10, 11, 12 and df-1176-178.. .
The Regents Of The University Of California

Intragastric volume-occupying device and fabricating same

Intragastric volume-occupying devices and methods for treating obesity are provided. The devices, which are inflated by carbon dioxide, include an aluminum or silicon oxide barrier layer providing carbon dioxide retention and an alkylene vinyl alcohol polymer layer providing structural integrity in vivo..
Obalon Therapeutics, Inc.

Mirna modulators of thermogenesis

Provided are novel methods and compositions for the modulation of thermogenesis. Such methods are particularly advantageous in that they allow for the reduction of body fat in a subject without the subject having to adjust their caloric intake through dieting, modify their physical activity or undergo bariatric surgery.
Aptamir Therapeutics, Inc.

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Provided herein are therapies, and methods using that therapy, in the treatment of one or more of type 2 diabetes (t2d), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population..
The University Of British Columbia

Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia

A combination of albuterol and caffeine can be used to reduce fat body mass or to increase lean body mass. The combination may be used to treat conditions such as obesity or sarcopenia.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating gpr30/gper activity

The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of gpr30/gper for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ros)..
Stc. Unm

Composition and treating metabolic disorders

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (t2dm) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex.
Veroscience Llc

Use of glycomacropeptide to improve women's health

Gmp-containing compositions can be used according to the disclosed methods to treat obesity and related metabolic conditions, or to treat or prevent osteoporosis, osteopenia, and other conditions related to loss of bone mineral content or bone strength.. .

Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University

Preeclampsia

The invention provides a method of treating preeclampsia, fetal growth restriction (fgr or iugr), obesity in pregnancy, post-partum cardiomyopathy (heart failure in mothers), cancer and diabetic retinopathy, cardiomyopathy, myocardial infarction, wet microdegeneration and other disorders where angiogenesis is aberrant either diminished or exacerbated, comprising modulating the activity of micro rna (mirna). Also provided are an mirna modulator or a combination thereof or functional fragments or homologues thereof for use in the treatment of preeclampsia, fetal growth restriction, obesity in pregnancy, cancer, and diabetic retinopathy, cardiomyocyte infarction, wet microdegeneration as well as other disorder where angiogenesis is aberrant either diminished or exacerbated.
Aston University

Administration of nicotinamide mononucleotide in the treatment of disease

Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (nmn) to a subject.
Washington University

Fumagillol derivatives

Stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein r1 and r2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with metap2..

Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof

The invention provides novel conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or r-(+)-α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or cinnamic acid, or cholic acid, or oleanolic acid, or salicylic acid, or betulinic acid, or chlorogenic acid, or caffeic acid, or bassic acid, or acetyl l-carnitine, or s-allyl cysteine sulphoxide, or s-methyl cysteine sulfoxide, or pantothenic acid, or ascorbic acid, or retinoic acid, or nicotinic acid, or biotin, or a derivative or analog thereof, and a moiety derived from berberine or l-carnitine or metformin or unsaturated fatty acid, or a derivative or analog thereof. The invention also relates to pharmaceutical compositions, methods of preparation and use of these conjugates in treating and/or preventing, for example, liver diseases or disorders, various diabetes, diabetic complications, dyslipidemia, obesity, metabolic syndromes, pre-diabetes, muscle atrophy, inflammation, and cancers.
Shenzhen Hjghtide-biopharmageutical, Ltd.

Ultrasonic locating and/or characterizing intragastric devices

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Summit Innovation Labs Llc

. .

Substituted bridged urea analogs as sirtuin modulators

Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Vascular calcification prevention and treatment

The invention encompasses compositions and methods for effectively interfering, reducing and preventing conversion of vascular smooth muscle cells (vsmcs) and circulating stem cells to osteoblastic bone-like cells, thereby reducing and/or preventing vascular calcification (vc) or calcium mineral (hydroxyapatite) deposition in the vasculature. The severity and extent of calcification in the major arteries reflect atherosclerotic plaque burden and strongly predict cardiovascular morbidity and mortality.
Summit Innovation Labs Llc

Metabolic syndrome treatment

Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc

C16:1n7-palmitoleate and derivatives thereof for treating obesity, promoting weight loss, and supporting weight management

The present technology provides methods for treating obesity, promoting weight loss, and supporting weight management in a subject in need thereof. The methods include administering to the subject an effective amount of a composition comprising one or more of c16:1n7-palmitoleate, derivatives thereof, or pharmaceutically acceptable salts thereof..
Tersus Life Sciences, Llc

Treatment and prevention of diabetes and obesity

Since the present compositions are aimed toward normalizing metabolism and energy expenditure and managing oxidative stress and inflammation, they are also beneficial in relation to physical activity, in particular performance, endurance, fatigue and recovery during intensive and continuous exercise/exertion.. .

Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors

Wherein the groups r1, r2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin o-acyl transferase (goat) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity..

Substituted quinolines as pde-10 inhibitors

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes..
Sunovion Pharmaceuticals Inc.

Compounds and methods for inducing browning of white adipose tissue

The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula i, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes..
Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Dermatopontin as a therapeutic for metabolic disorders

The present disclosure describes to a method of treating a metabolic disease in a subject, wherein the method comprises administration of dermatopontin to a subject, wherein the dermatopontin is recombinant dermatopontin and the metabolic disease is selected from a group consisting of weight gain, diet-induced weight gain, obesity, morbid obesity, metabolic syndrome, glucose homeostasis, insulin resistance, type i diabetes, type if diabetes and cardiovascular disease. Disclosed herein is also a method of determining or making a prognosis of a subject's susceptibility to metabolic diseases and obesity, the method comprising measuring the level of circulating dermatopontin in a sample obtained from a subject; and comparing the level of circulating dermatopontin obtained with the level of dermatopontin previously determined in a control; and determining the susceptibility of the subject to metabolic disease and obesity based on the difference between the level of circulating dermatopontin and the level of dermatopontin in the control..
Agency For Science, Technology And Research

Devices, solutions and methods for sample collection related applications, analysis and diagnosis

A solution is described for preserving cells and/or extra-cellular components in naturally expressed bodily fluids (e.g. Saliva, sputum, urine) for further downstream analysis and/or for diagnosis of a medical condition.
Abogen, Inc.

Mixture of purified sods of plant origin

The present invention relates to an original and specific mixture of purified superoxide dismutases (sods) of plant origin, characterised in that said mixture is essentially made up of three superoxide dismutases: a manganese superoxide dismutase, a copper and zinc superoxide dismutase and an iron superoxide dismutase provided in two isoforms, which can be obtained from an extract of the hybrid variety f1 of cucumis melo ma 7950 or the cells thereof cultured in vitro or by transfer and expression of the genes of said sods in prokaryotic or eukaryotic cells. The specific mixture according to the invention imparts to the compositions containing same a greater effectiveness in the treatment or prevention of diseases linked to inflammatory and/or oxidative stress, such as radiation-induced fibroses, cardiovascular diseases, obesity, atherosclerosis, labial herpes and myopathies, as well as in nutritional, pharmaceutical, veterinary or cosmetic uses..
Bionov

Compositions and methods for treating fatty tissue buildup

The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Apelin fusion proteins and uses thereof

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.

Compositions and methods for treating obesity and hyperphagia

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as prader-willi syndrome, obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
Mhs Care-innovation Llc

Slim and aqua concentrate having standardized and triple salt stabilized (-)-hydroxycitric acid from garcinia cambogia extract for making concentrate and slimming water and their derived product for weight management

The present invention discloses a slim and aqueous extract of garcinia cambogia comprising (−)-hydroxycitric acid as dietary product for weight management. The present invention also discloses a process of preparation of aqueous extract wherein the garcinia cambogia fruit rinds are subjected to cold circulation to retain the phytochemical components and the aqueous extract is adjusted to neutral ph and stabilized with triple mineral salt of calcium, magnesium and potassium and decolorized using activated carbon.
Phytotech Extracts Private Limited

Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (gerd), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (gejac), infections due to bacteria that are resistant to antibiotics, including methicillin-resistant staphylococcus aureus (mrsa), clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota..
New York University

Contact area diffusion factor for quantifying fat contents of liquid

A method for determining the presence of fats in the body fluid by photographing a body fluid droplet and calculating the change of the contact area of the body fluid droplet and the contact area diffusion factor. In addition, fats may be easily detected by using a simple filming equipment where it is required to detect fats such as liposuctions, various orthopedic operations, obesity managements, etc..

Screening compound having obesity preventive or therapeutic activity

To provide a screening method for a substance having an anti-obesity action and an anti-obesity drug. A screening method including: a step for contacting a test substance and a synoviolin-gene-expressing cell; and a step for verifying the effect of the test substance on the synoviolin gene expression, or the effect thereof on synoviolin protein activity.

Bifidobacteria for treating diabetes and related conditions

This invention relates to new uses of bifidobacteria (particularly, although not exclusively, probiotic bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions..
Dupont Nutrition Biosciences Aps

Acylated glucagon analogues

The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral ph, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Methods of treating an overweight or obese subject

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a metap-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject..
Zafgen, Inc.

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue, in embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms..
Neurotronic, Inc.

Drug for inhibiting adipose cell differentiation and insulin resistance

The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be yh-16, mes, myh-16, m003, m007, mz101, or the like..
Beijing Protgen Ltd.

Use of flibanserin in the treatment of obesity

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.. .
Sprout Pharmaceuticals, Inc.

Pharmaceutical composition for the treatment of obesity

The present invention relates to a layered pharmaceutical composition comprising: a first layer of sustained-release bupropion or its pharmaceutically acceptable salts, a second layer of sustained-release naltrexone or its pharmaceutically acceptable salts, with pharmaceutically acceptable excipients, and an intermediate inert layer that provides a time-controlled disintegration to allow separation of two drug layers and maintain their physical integrity as a single tablet. It further provides the methods for preparing the said pharmaceutical compositions for the treatment of obesity-related conditions..
Intas Pharmaceuticals Ltd.

Modulating adipose tissue and adipogenesis

The invention relates to the field of obesity and related metabolic diseases. More specifically, the invention relates to methods of reducing aggrecanase activity or antigen in mammals in order to enhance brown adipose tissue (bat) development, to promote conversion of white adipose tissue (wat) into bat in vivo, and to limit triglyceride accumulation and steatosis in the liver.
Katholieke Universiteit Leuven Ku Leuven Research & Development

Glucagon-receptor selective polypeptides and methods of use thereof

This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon.
Intarcia Therapeutics Inc.

Isoquinoline derivatives as mgat2 inhibitors

The compounds of formula i act as mgat2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.. .
Merck Sharp & Dohme Corp.

Intragastric device

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided..
Obalon Therapeutics, Inc.

Methods of treating or preventing overweight and obsesity in mammals by administering a composition comprising mannoheptulose

The present invention is based on the discovery that mannoheptulose (mhep) reduces or inhibits the differentiation process of fat stem cells into adipocytes so as to decrease the body's fat storage capacity. Compositions comprising a mhep, process of making the compositions, and methods of using the compositions for treating or preventing overweight and obesity in a mammal, such as, for example, a growing pet (e.g., puppy, kitten), or a spayed/neutered pet, are encompassed by the present invention..
Waterwise Gardening Llc

Glucagon derivatives

The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity..
Hanmi Pharm. Co., Ltd.

Partially saturated tricyclic compounds and methods of making and using same

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided.
Zafgen, Inc.

Dry powder drug delivery system and methods

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity..
Mannkind Corporation

Stable pharmaceutical solution formulation of glp-1r antibody fusion protein

Disclosed is a stable pharmaceutical solution formulation of a glp-1r antibody fusion protein, comprising a therapeutically effective amount of the glp-1r antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mm, the final concentration of the surfactant is 0.01%-0.5%, and the ph value of the stable solution formulation is from 5.0 to 8.0.
Gmax Biopharm Llc.

Method of treating or ameliorating type 1 diabetes using fgf21

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Amgen Inc.